早期手术干预在小肠克罗恩病治疗中的价值  

Value of Early Surgery in Small Intestinal Crohn’s Disease

作　　者：郝秀秀 俞旻皓[1] 钟鸣[1] HAO Xiuxiu;YU Minhao;ZHONG Ming(Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai ,200127)

机构地区：[1]上海交通大学医学院附属仁济医院胃肠外科,200127

出　　处：《胃肠病学》2020年第4期246-249,共4页Chinese Journal of Gastroenterology

基　　金：国家自然科学基金青年科学基金项目(81702300);国家自然科学基金面上项目(81873555)。

摘　　要：克罗恩病(CD)是一种胃肠道慢性炎症性疾病,其发病率在全球呈上升趋势。CD治疗的重点是症状控制和肠黏膜愈合,从而改善患者的生活质量、预防并发症。对具有高危因素的CD患者早期应用抗TNF药物如英夫利西单抗(IFX)已逐渐成为CD患者主要的临床治疗方案。然而,IFX治疗有其局限性,早期手术可能使CD患者的获益更大。本文就早期手术干预在小肠CD中的治疗价值作一综述。Crohn’s disease(CD)is a gastrointestinal tract chronic inflammatory disease with an increasing incidence worldwide.Treatment of CD is focused on symptom control and healing the intestinal mucosa in order to improve the quality of life and prevent complications.The early use of anti-TNF agents such as infliximab in CD patients with high risk factors has become the main treatment of CD clinically.However,infliximab has its limitations,early surgery might benefit the patient more.This article reviewed the therapeutic value of early surgery in small intestinal CD.

关 键 词：CROHN病 早期手术 英夫利西单抗 治疗 

分 类 号：R57[医药卫生—消化系统]